The full text of this article
Licencing as a commercialisation strategy under different institutional contexts: a comparative empirical analysis of German and Chinese biotechnology firms
by Yantai Chen, Michael Dowling, Roland Helm
International Journal of Business and Globalisation (IJBG), Vol. 7, No. 2, 2011
Abstract: The aim of this study is to investigate how country differences between German and Chinese biotechnology firms affect the usage of licencing as a commercialisation strategy for future development. Firms in the biotechnology industry especially can use this strategy to gain access to the marketplaces, since such firms are often not fully integrated and do not concentrate on the early steps in the biotechnology value chain, such as research and testing. We examine the use of licencing as a commercialisation strategy in Germany and China. In Germany, we studied firms in biotechnology regional networks in Bayern. All regions were selected to ensure a high structural comparability, but they also differ systematically concerning the products manufactured. In China, we focused on biotechnology companies in Yangtze River Delta region (Shanghai, Jiangsu and Zhejiang). These data are compared with similar data collected previously in the USA. Based on the empirical data, innovation capacity, the structure of patent owners and incentive mechanism, the regulatory and IPR regimes of different countries are illustrated to explain the differences.
Online publication date: Sat, 06-Aug-2011
is only available to individual subscribers or to users at subscribing institutions.
Go to Inderscience Online Journals to access the Full Text of this article.
Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.
Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Business and Globalisation (IJBG):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable).
See our Orders page to subscribe.
If you still need assistance, please email firstname.lastname@example.org